The capacity to reprogram adult patient cells into pluripotent, embryonic-like, stem cells by nuclear transfer has been reported as a breakthrough by scientists from the US and the Hebrew University of Jerusalem.
The work, described in the journal Nature, was accomplished by researchers from the New York Stem Cell Foundation Research Institute and Columbia University and by Nissim Benvenisty, the Herbert Cohn professor of Cancer Research and director of the Stem Cell Unit at the Institute of Life Sciences at the Hebrew University of Jerusalem, and his graduate student Ido Sagi. The latter assisted in the characterization of the pluripotent
Image via Wikipedia
Scientists have developed a new tool that illuminates connections between stem cells and cancer.
Researchers have been successful in breaking apart human prostate tissue, extract the stem cells in the tissue, and alter those cells genetically so that they spur cancer.
Many tissues contain pools of stem cells that replenish the tissue when it’s damaged or when changes take place. For example, stem cells in the skin produce new cells to replace those irreparably damaged by the sun, and stem cells in the breast create milk-producing cells when a woman is pregnant.
A characteristic of these stem cells is that
An experimental drug is on the way, which might be effective to fight brain cancer (glioblastoma) and prostate cancer.
The researchers are experimenting on this drug at the University of Texas Southwestern Medical Centre (UTSMC).
According to Jerry Shay, professor of cell biology, the drugs are promisisng because they attack not only the tumour cells but also the rare cancer stem cells in the body. So, it would be effective to root out cancer from the body.
“Because it attacks a mechanism that’s active in most cancers, it might prove to be widely useful, especially when combined with other therapies,” said Shay.
An experimental drug currently being tested against breast and lung cancer shows promise in fighting the brain cancer glioblastoma and prostate cancer, researchers at UT Southwestern Medical Center have found in two preclinical studies.
The drug’s actions, observed in isolated human cells in one trial and in rodents in the other, are especially encouraging because they attacked not only the bulk of the tumor cells but also the rare cancer stem cells that are believed to be responsible for most of a cancer’s growth, said Dr. Jerry Shay, professor of cell biology and a senior co-author of both papers. The
Image via Wikipedia
Taming the bad cancer stem cells, genetically modifying them to arm them against disease and cancer-from defusing the bomb. Bet on cell girls ‘GM’, transformed into cancer killer bullets, one of five projects funded by AIRC (Italian Association for Cancer Research) with 60 million in five years thanks to the funds of 5 per thousand.
Studies of molecular oncology clinic, chosen by a jury of 18 super-foreign experts, who share one big final goal: to train a new generation of physicians, researchers are able to bridge the gap between the lab bench and the bedside. In five years’